Work

Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas

Year: 2021

Type: article

Abstract: Targeted therapies have revolutionized cancer treatment. It is well established that alterations of chromatin configuration and modifications affect tumorigenesis of some, possibly most, bone and soft-tissue sarcomas. As epigenetic regulators play a major role in the development of bone and soft-tissue sarcomas, epigenetic drugs provide a novel potential avenue for rational targeted therapies for these aggressive cancers. The present review summarizes the application of epigenetic drugs for clinical utilization in bone and soft-tissue sarcomas and provides an overview of clinical trials currently evaluating epigenetic therapies in this space.

Source: Sarcoma

DOI: 10.1155/2021/5575444

Authors: Jun Wang, Arielle Elkrief, Wei Guo, Neerav Shukla, Mrinal Gounder, Marc Ladanyi

Institutions: Memorial Sloan Kettering Cancer Center, Peking University People's Hospital

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $820